Current AI applications in lung cancer related to radiologic imaging, digital pathology, genomics, immunohistochemistry, and Cell Painting morphology are examined and their potential to be incorporated into a proposed multimodal model is examined.
Abstract
Simple Summary Lung cancer remains the leading cause of cancer-related deaths. Non-small cell lung cancer accounts for most cases, many of whom are on immunotherapy. Current clinical practice relies on a single biomarker, like PD-L1 and tumor mutation burden, to make decisions on immunotherapy treatments. However, both biomarkers have reported inconsistent results in terms of predictive value for immunotherapy response and are thus not precise biomarkers. Therefore, a more robust method is needed to be able to accurately predict outcomes of interest in lung cancer, such as treatment response, treatment selection and diagnosis. Multimodal AI has the potential to revolutionize lung cancer treatment by integrating multiple different data types into a single framework to predict such outcomes. In this review, we examine current AI applications in lung cancer related to radiologic imaging, digital pathology, genomics, immunohistochemistry, and Cell Painting morphology and their potential to be incorporated into a proposed multimodal model.
The role of multimodal artificial intelligence and machine learning in bridging the gap in interpreting heterogeneous modalities to improve risk prediction, prognostic assessment, and treatment decision-making in precision oncology is focused on.
Shruthi Suresh, A. Parvathy, Megha Raj et al.· Frontiers in Digital Health· 0 citations
Non-small cell lung cancer (NSCLC) is characterized by profound biological heterogeneity, frequently leading to late-stage diagnosis, recurrence, or metastasis. Conventional clinical pathways heavily depend on subjective visual interpretations, invasive tissue biopsies, and experience-based medical models that constrai...
Shuai-Yu Zheng, Chi Lv, Zhen Yao· Frontiers in Medicine· 0 citations
Lung cancer continues to be a predominant global cause of death. Clinical outcomes are significantly influenced by the timely identification of high-risk populations, accurate diagnosis, and appropriate therapy selection. Progress in artificial intelligence (AI), liquid biopsy, and immunotherapy has opened new avenues...
G. Pranowo, Gilang Prayoga Putra Permana, D. Selvyana· Indonesian Journal of Health...· 0 citations
For driver-negative advanced non-small cell lung cancer (NSCLC), immune checkpoint inhibitors (ICIs) have been established as the standard therapy, but only a few patients can achieve lasting clinical benefits, and reliable non-invasively predictive tools are urgently needed in clinical practice. CT radiomics can non-i...
Min-Rui Liu, Jing Song· 2026 7th International Confe...· 0 citations
Immunotherapy is increasingly reshaping the therapeutic landscape of clinical oncology by inducing effective tumor regression and durable responses in various types of human cancers. However, a substantial fraction of patients resist immunotherapy, or even experience relapse after an initial response. Clinically, the c...
Wen-Jie Zhang, Ze-Yu Luo, Kai-Wen Liu et al.· Science Bulletin· 0 citations
Machine-learning networks can learn without detailed instructions from a designer. Those that do may offer insight into how the brain reorganizes itself during learning.
MIT News · Artificial Intelligence· news.mit.eduJul 15, 2026
Assistant Professor Pat Pataranutaporn describes a new interface that lets everyday users glimpse inside an AI's neural network before their chatbot ever says a word.
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.